Quoin Pharmaceuticals Ltd DRC (QNRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $17.78M
Last updated: Nov 17, 2026 at 11:06 AM ET
Quoin Pharmaceuticals Ltd DRC (QNRX) Stock Forecast
Analysts expect Quoin Pharmaceuticals Ltd DRC (QNRX) to earn -$5.25 per share in the fiscal year ending Dec 31, 2026. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.86, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 6 | 85.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$5.25
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$2.71
- EPS consensus
- Fiscal year ending Dec 31, 2028
- -$1.06
- EPS consensus, revenue $20.74M
- Next report
- Mar 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$5.25 | -$5.25 to -$5.25 | 1 | N/A | N/A | 7 |
| Dec 31, 2027 | -$2.71 | -$3.50 to -$1.92 | 2 | N/A | N/A | 6 |
| Dec 31, 2028 | -$1.06 | -$1.19 to -$0.93 | 2 | $20.74M | $15.71M to $25.78M | 3 |
Quarterly Estimates
The EPS consensus rises from -$1.20 for the quarter ending Dec 31, 2026 to -$1.07 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.20 | -$2.10 to -$0.64 | 8 |
| Mar 31, 2027 | -$1.07 | -$1.07 to -$1.07 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$6.88.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$5.25 | -$7.17 | -$7.17 | -$7.17 | -$6.88 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.71 | -$3.19 | -$3.19 | -$3.19 | -$2.91 | N/A |
| Quarter ending Mar 31, 2027 | -$1.07 | -$1.46 | -$1.46 | -$1.46 | N/A | N/A |
Frequently Asked Questions About QNRX
What is the QNRX stock forecast?
Consensus analyst estimates put Quoin Pharmaceuticals Ltd DRC's EPS at -$5.25 for the fiscal year ending Dec 31, 2026. The consensus rating from 7 analysts is Buy.
How do analysts rate QNRX stock?
Of 7 analysts covering Quoin Pharmaceuticals Ltd DRC, 1 rates it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from QNRX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$5.25, with estimates from -$5.25 to -$5.25 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.71, with estimates from -$3.50 to -$1.92 from 2 analysts.
What revenue do analysts expect from Quoin Pharmaceuticals Ltd DRC next year?
For the fiscal year ending Dec 31, 2028, the consensus revenue estimate is $20.74M, with estimates from $15.71M to $25.78M.
How many analysts cover QNRX?
7 analysts rate Quoin Pharmaceuticals Ltd DRC stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
QNRX pages: Overview, Earnings, Forecast, Financials, Competitors